Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H36N2O5 |
| Molecular Weight | 468.5851 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C=C2[C@H](CN(C)CCCN3CCC4=CC(OC)=C(OC)C=C4CC3=O)CC2=C1
InChI
InChIKey=ACRHBAYQBXXRTO-NRFANRHFSA-N
InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m0/s1
IVABRADINE, (-)- is an (R)-enantiomers of Ivabradine. IVABRADINE, (-)- produced a concentration-dependent block of hKv1.5 channels. S 16260 (R configuration) and S 16257 (S configuration) of Ivabradine were equipotent in reducing the spontaneous firing of rabbit sinus node preparations, but S 16260 induced significant prolongations of action potential duration of ventricular preparation (guinea pig papillary muscle and rabbit purkinje fibers), contrary to S 16257. These in vitro data have been confirmed by in vivo studies in anesthetized pigs showing the equipotence of the two isomers in reducing the heart rate, the absence of effect of S 16257 on the QT interval corrected for heart rate (QTc) in contrast with S 16260 which induced a dose-dependent increase in the QTc, indicating a direct effect on ventricular repolarization.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of the two enantiomers, S-16257-2 and S-16260-2, of a new bradycardic agent on guinea-pig isolated cardiac preparations. | 1995 Jul |
|
| Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2. | 1996 Mar |
|
| Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. | 1997 Nov 19 |
|
| The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease. | 2006 May |
Patents
Sample Use Guides
Four consecutives doses 0.03, 0.1, 0.3 and 1 mg/kg (at 30 min intervals).
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID90168224
Created by
admin on Sat Dec 16 10:42:46 GMT 2023 , Edited by admin on Sat Dec 16 10:42:46 GMT 2023
|
PRIMARY | |||
|
167072-91-5
Created by
admin on Sat Dec 16 10:42:46 GMT 2023 , Edited by admin on Sat Dec 16 10:42:46 GMT 2023
|
PRIMARY | |||
|
9T270O3E9P
Created by
admin on Sat Dec 16 10:42:46 GMT 2023 , Edited by admin on Sat Dec 16 10:42:46 GMT 2023
|
PRIMARY | |||
|
21625941
Created by
admin on Sat Dec 16 10:42:46 GMT 2023 , Edited by admin on Sat Dec 16 10:42:46 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
